Siltuximab for multicentric Castleman’s disease: a randomised, double-blind, placebo-controlled trial - van Rhee, F; Wong, R S; Munshi, N; Rossi, J-F; Ke, X-Y; Fosså, A (Lancet Oncol, 2014)
et al.